Potassium%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an electrolyte replacement medication used to treat and prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment and prevention of hypokalemia. * Potassium supplementation in patients with significant potassium losses (e.g., due to diuretics, vomiting, diarrhea, hyperaldosteronism). ## Adult Dosing * **Oral:** * **Prevention:** Typically 20 mEq (10 mmol) per day, given in one or two divided doses. * **Treatment:** 40-100 mEq (20-50 mmol) per day, given in two to four divided doses. * Maximum single oral dose: Generally not to exceed 20 mEq (10 mmol) per dose for liquid or slow-release formulations to minimize GI irritation. * Maximum daily oral dose: Typically not to exceed 200 mEq (100 mmol) per day. * **Intravenous (IV):** * **Prevention:** 20-40 mEq (10-20 mmol) per day, added to IV fluids. * **Treatment:** 40-100 mEq (20-50 mmol) per day, added to IV fluids. * **Severe Hypokalemia/Life-threatening Arrhythmias:** May require higher doses, administered with continuous cardiac monitoring and infusion pump. Dosing often guided by local protocol. * **Maximum Infusion Rate:** * Peripheral line: Typically not to exceed 10 mEq (5 mmol) per hour. * Central line: May be infused at rates up to 20 mEq (10 mmol) per hour, but only with continuous ECG monitoring. Rates >10 mEq/hr should be reserved for documented severe hypokalemia or ongoing losses. * **Maximum Concentration:** * Peripheral line: Typically 40 mEq (20 mmol) per liter of IV fluid. * Central line: May be concentrated up to 80 mEq (40 mmol) per liter, but usually not exceeding 100 mEq (50 mmol) per liter even in critical situations, depending on clinical judgment and monitoring. ## Pediatric Dosing * Dosing varies widely based on age, weight, severity of potassium deficit, and clinical condition. Specific dosing should be determined by local protocol or based on calculated needs. * **General Guidelines (Oral):** * Typical daily maintenance: 1-2 mEq/kg/day (0.5-1 mmol/kg/day). * Maximum daily dose: Often limited to 3 mEq/kg/day (1.5 mmol/kg/day) or 40 mEq/day (20 mmol/day), whichever is less. * **General Guidelines (Intravenous):** * Infusion rates and concentrations are typically lower than in adults and depend on age and cardiovascular status. * Peripheral infusions generally limited to 0.1 mEq/kg/hour (0.05 mmol/kg/hour) or 10 mEq/hour (5 mmol/hour), whichever is less. * Central line infusions may be faster, with careful monitoring. * Concentrations generally should not exceed 40 mEq/L (20 mmol/L). ## Dose Adjustments * **Renal Impairment:** Dose must be significantly reduced or avoided in patients with renal insufficiency due to the risk of hyperkalemia. Close monitoring of renal function and serum potassium is crucial. ## Contraindications * Severe renal impairment. * Conditions where hyperkalemia is already present (e.g., anuria, oliguria, severe untreated Addison's disease). * Hyperkalemia. * Certain types of heart block. * Untreated Addison's disease. * Patients receiving potassium-sparing diuretics unless hypokalemia is severe and other measures are ineffective. ## Adverse Effects * **Gastrointestinal (Oral):** Nausea, vomiting, abdominal pain, diarrhea, GI bleeding, ulceration, and perforation (especially with undiluted or slow-release formulations). * **Cardiovascular (IV):** Arrhythmias, cardiac arrest (especially with rapid IV infusion or hyperkalemia). * **General:** Hyperkalemia (muscle weakness, fatigue, paresthesias, confusion, arrhythmias, cardiac arrest), phlebitis (IV). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors, Angiotensin II Receptor Blockers (ARBs):** Can increase serum potassium levels, increasing the risk of hyperkalemia. * **NSAIDs:** May reduce the effect of potassium supplements and increase the risk of hyperkalemia. * **Heparin:** May increase serum potassium levels. * **Salt substitutes:** Often contain potassium chloride, leading to increased potassium intake. ## Monitoring * Serum potassium levels (frequently, especially during IV administration or dose adjustments). * Renal function (BUN, creatinine). * ECG (especially with IV administration, rapid infusion rates, or suspected hyperkalemia). * Signs and symptoms of hypokalemia and hyperkalemia. * Urine output. ## Clinical Pearls * Oral potassium chloride should be diluted in at least 4 ounces (120 mL) of water or juice to minimize GI irritation. * Slow-release formulations may reduce GI side effects but can also lead to variable absorption. * IV potassium chloride should always be diluted and administered with caution via an infusion pump. Never administer as a rapid IV bolus. * When correcting severe hypokalemia, concomitant magnesium replacement may be necessary as magnesium deficiency can impair potassium repletion. * Monitor for signs of hyperkalemia closely, especially in patients with renal impairment or those taking interacting medications. *** *This information is intended for healthcare professionals and does not replace a thorough review of current prescribing information, clinical guidelines, or institutional protocols. Always verify current drug information before making clinical decisions.*